gms | German Medical Science

70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12.05. - 15.05.2019, Würzburg

Ribosomal protein S27 (RPS27) – A new marker for astrocytic tumours?

Das ribosomale Protein S27 (RPS27) – Ein neuer Marker für astrozytäre Tumoren?

Meeting Abstract

  • presenting/speaker Jonas Feldheim - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Almuth F. Kessler - Universität Würzburg, Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Camelia Monoranu - Universität Würzburg, Institut für Pathologie, Würzburg, Deutschland
  • Julia Krapp - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Dominik Schmitt - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Lara Wilczek - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Ralf-Ingo Ernestus - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Mario Löhr - Universität Würzburg, Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland
  • Carsten Hagemann - Universität Würzburg, Klinik für Neurochirurgie, Tumorbiologie, Würzburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie. Würzburg, 12.-15.05.2019. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocV255

doi: 10.3205/19dgnc274, urn:nbn:de:0183-19dgnc2744

Published: May 8, 2019

© 2019 Feldheim et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Ribosomal protein S27 (RPS27) shows a strong nuclear staining in Purkinje cells. However, it has been reported to be mutated or overexpressed in multiple human cancers, such as colon or breast cancer. In melanoma, RPS27 mutations are even discussed as driver mutations. Since there are no data on RPS27 expression in primary brain tumours available yet, we aimed to analyse its expression patterns in astrocytic tumours of different WHO grades.

Methods: We extracted mRNA from frozen samples of normal brain specimens (n=9, NB), astrocytoma WHO grade II (n=15, LGA) and glioblastoma multiforme (n=78, GBM) with varying biological behaviour, i.e. primary local tumours leading to local relapse (primary tumours n=24; relapse n=4), primary local tumours leading to multifocal relapse (primary tumours n=12; relapse n=3) and primary multifocal tumours (n=7). RPS27 expression was measured by quantitative PCR (qPCR). Furthermore, we immunohistochemically stained paraffin-embedded sections of these tumour samples for RPS27 protein expression. RPS27 expression was correlated with progression-free and overall survival (Kaplan Meyer analyses, Breslow) and with the different growth patterns in GBM (ANOVA).

Results: The immunohistochemistry confirmed the expression of RPS27 in Purkinje cells. Interestingly, we also observed strong staining of astrocytic tumour cells, whereas physiological astrocytes were negative. In comparison to NB, RPS27 mRNA was overexpressed in LGA (median 2.5 fold, p=0.02), as well as in GBM (median 2.8 fold, p=0.02). There was no difference in RPS27 mRNA expression between LGA and GBM (p>0.05). Primary GBM showed a similar expression, independently of their growth pattern (primary local tumours with local/multifocal relapse and primary multifocal tumours, p>0.05). Similarly, there was no significant difference between primary tumours and their respective relapses. RPS27 mRNA expression was not associated with a difference in overall or progression-free survival of the patients.

Conclusion: RPS27 mRNA expression was increased in GBM, irrespective of their growth patterns. Since there was no difference between LGA and GBM, we suppose that RPS27 dysregulation is an early step in glioma-genesis. This observation supports the hypothesis that RPS27 might serve as a new molecular marker in astrocytic tumours of different WHO grades.